According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “
Several other brokerages have also commented on NH. Cowen and Company started coverage on NantHealth in a research note on Monday, June 27th. They set an outperform rating and a $19.00 price target on the stock. Canaccord Genuity restated a buy rating and set a $17.00 price target on shares of NantHealth in a research note on Monday, September 19th. Jefferies Group started coverage on NantHealth in a research note on Monday, June 27th. They set a buy rating on the stock. FBR & Co restated a buy rating on shares of NantHealth in a research note on Thursday, August 18th. Finally, First Analysis started coverage on NantHealth in a research note on Monday, June 27th. They set an overweight rating and a $18.00 price target on the stock. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $18.00.
Shares of NantHealth (NYSE:NH) traded down 1.94% during mid-day trading on Thursday, hitting $13.16. 31,498 shares of the stock were exchanged. The firm’s market cap is $1.60 billion. NantHealth has a 12 month low of $9.79 and a 12 month high of $16.63. The stock’s 50 day moving average is $12.88 and its 200 day moving average is $12.64.
NantHealth (NYSE:NH) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.26. The firm had revenue of $31.50 million for the quarter, compared to analysts’ expectations of $23.55 million. The business’s quarterly revenue was up 166.9% compared to the same quarter last year. Analysts expect that NantHealth will post ($0.59) EPS for the current fiscal year.
A number of large investors have recently modified their holdings of the stock. Blackstone Group L.P. bought a new stake in shares of NantHealth during the second quarter worth $7,463,000. Jefferies Group LLC bought a new stake in shares of NantHealth during the second quarter worth $6,943,000. Wildcat Capital Management LLC bought a new stake in shares of NantHealth during the second quarter worth $3,008,000. Finally, FMR LLC bought a new stake in shares of NantHealth during the second quarter worth $11,250,000.
NantHealth, Inc, formerly Nant Health, LLC, is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.